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Figure 1. Extracellular matrix degradation. Bovine FDC explants were
cultured with indicated treatments for 27 days. Supernatant were moni-
tored by biomarkers of cartilage degradation C2M, AGNx1 and AGNx2
(Nordic Bioscience A/S). Values are mean  SEM. One-way ANOVA was
used to compare each bar with its respective W/O. *P < 0.05, **P < 0.01.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S76Conclusions: This study shows that in patients with hip OA the urinary
biochemical markers uCTX-II and uCIIM are not cross-sectionally
associated with hip pain during the 2-year follow-up. However, the
uCTX-II level at baseline could predict a progressive or moderate hip
pain trajectory over a two-year follow-up period.
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EXTRACELLULAR MATRIX CHANGES IN RESPONSE TO RECOMBINANT
HUMAN FIBROBLAST GROWTH FACTOR 18 STUDIED IN EX VIVO
CULTURES OF ARTICULAR CARTILAGE
D. Reker y, T. Christiansen z, M. Karsdal y, A. Bay-Jensen y. yNordic BioSci.
A/S, Herlev, Denmark; zOrthopedic Dept., Gentofte Univ. Hosp., Hellerup,
Denmark
Purpose: Osteoarthritis (OA) is a degenerative disease with high
prevalence, creating an unmet medical need for drugs to regenerate
cartilage. A promising candidate for a novel disease modifying osteo-
arthritis drug (DMOAD) is Sprifermin, a truncated form of ﬁbroblast
growth factor 18 (FGF18). Sprifermin has been demonstrated to
increase cartilage volume in the knees of OA patients, but surprisingly
little is known about the mode of action behind its anabolic effects.
The few studies published indicate that full-length FGF18 induces
cartilage formation by increasing chondrocyte proliferation, resulting
in increased overall matrix production by the larger population of
chondrocytes. Our hypothesis is that matrix degradation is initially
needed during this process in order to expand the lacunae and make
room in the matrix for the new chondrocytes. Accordingly, the aim of
this study was to characterize the changes in matrix degradation
occurring in response to direct stimulation with recombinant human
(rh) FGF18.
Methods: Full depth cartilage explants (FDCex) punched from bovine
articular cartilage were cultured for 27 days. In replicates of six, the
FDCex were treated with various concentrations of full-length rhFGF18
(1, 10, 50, 100 or 500 ng/mL rhFGF18), an anabolic cytokine as positive
control for cartilage formation (100 ng/mL IGF-I), or culture media
without treatment as negative control (W/O). Supernatants were har-
vested and replaced 3 times weekly. Cell viability was measured using
AlamarBlue at day 27. Biomarkers released to the supernatant were
measured using the following well-described ELISA; C2M and AGNx2
reﬂecting matrix metalloproteinase (MMP)-mediated degradation of
type II collagen and aggrecan, respectively, AGNx1 reﬂecting aggreca-
nase-mediated degradation of aggrecan, and C-Col10 reﬂecting chon-
drocyte hypertrophy. Mean values and standard error of the mean
(SEM) were compared using one-way ANOVA assuming normal dis-
tribution. Signiﬁcance levels are indicated by asterisks; *P < 0.05, **P <
0.01.
Results: To evaluate the changes in matrix degradation occurring in
the FDCex in response to direct stimulation with rhFGF18, three
different biomarkers of matrix degradation were quantiﬁed (ﬁgure
1). According to C2M, MMP-mediated type II collagen degradation is
signiﬁcantly decreased in response to  50 ng/mL rhFGF18 from day
11 onward (P < 0.05). Likewise, AGNx2 indicates a slight decrease
in MMP-mediated aggrecan degradation in response to  50 ng/mL
rhFGF18 from day 18 onward, although not signiﬁcant. On the
contrary, AGNx1 reveals increased aggrecanase-mediated aggrecan
degradation in response to  10 ng/mL rhFGF18 at day 25, although
only signiﬁcant for 50 ng/mL rhFGF18 (P < 0.05). Evaluation of the
chondrocytic changes occurring in response to rhFGF18, reveal a
dose-dependent increase in cell viability measured at day 27, and
no indication of hypertrophic cell differentiation, as assessed by C-
Col10.
Conclusions: The data presented here indicate that direct stim-
ulation of articular cartilage with rhFGF18 leads to decreased gen-
eration of MMP-mediated cleavage fragments of type II collagen and
aggrecan, but increased generation of the aggrecanase-mediated
cleavage fragment of aggrecan. Interestingly, AGNx2 is believed to be
a marker of cartilage degradation with impaired repair capacity,
whereas AGNx1 is considered a marker of reversible form cartilage
degradation. Accordingly, the increased AGNx1 could indicate the
matrix degradation needed for expansion of the lacunae, which
according to our hypothesis is needed to initiate the process of
cartilage formation. Clarifying the steps of this process is highly
important for the understanding of how a potential novel DMOAD is
affecting the tissue.121
URINE CROSSLINKED TELOPEPTIDE OF TYPE II COLLAGEN
PREDICTED OSTEOARTHRITIS PROGRESSION
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Purpose: The gold standard for assessing joint damage is still the plain
radiograph and this method only provides a historical view of the
skeletal damage that has already occurred. We cannot predict OA pro-
gression from the radiograph. In contrast, biomarkers are candidates to
predict an event that would occur in OA. One of the primary disease
processes of osteoarthritis is degradation of the type II collagen, which
is most abundant and highly speciﬁc for cartilage tissue. Crosslinked
telopeptide of type II collagen (CTX-II) was one of the speciﬁc marker of
type II collagen degradation in cartilage. Monitoring urine (u) CTX-II
was considered to be a potential biomarker in knee OA. It is reported
that uCTX-II was correlated with prevalence of radiographic OA and
higher uCTX-II had a increasing risk of having OA. However, there were
few reports about its role for prediction of OA progression. The purpose
of this study was to investigate whether uCTX-II could predict OA
progression.
Methods: This prospective cohort study protocol was approved by the
institutional review board of our university. One hundred and fourteen
painful medial knee OA patients were enrolled in this study. Some of the
patients were excluded due to data and follow up missing. Ninety one
patients (71.5y in average, men/female: 9/82) were analyzed. The basal
characteristics of the patients and a standing, extended antero-
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and 3 years later. Experienced readers read the radiographs inde-
pendently recorded the radiographic features of Kellgren & Lawrence
grading (K/L) grade and joint spacewidth (JSW). JSWwas determined at
the center point of the medial femoro-tibial compartment on a radio-
graph using a 0.1-mm graduated magnifying lens.Both serum and urine
samples were obtained on the day that baseline radiographs taken.
Measurement of uCTX-II was used commercial enzyme-linked immu-
nesorbent assay kit (CartiLaps; Nordic Bioscience, Herlev, Denmark).
uCTX-II values were corrected for urine creatinine concentration. As the
distribution of uCTX-II was found to be positively skewed, a logarithmic
transformation (natural log (Ln)) was therefore applied to these bio-
markers to obtain an approximately normal distribution. uCTX-II were
compared using parametric comparisons analysis of variance (ANOVA).
The Bonferroni correction for multiple comparisons was applied. Sig-
niﬁcant differences were evaluated t-test if ANOVAwas signiﬁcant. A P-
value of less than or equal to 0.05 was considered to be statistically
signiﬁcant.
Results: Of the 91patients, 7 showed K/L grade 1,16 showed K/L grade 2,
27 showed K/L grade 3 and 41 showed K/L grade 4 at the baseline. In the
3 years, 41 patients were received total knee arthroplasty (TKA). In the
other patients, 22 patients were progressed their K/L grade one ormore.
The ln-uCTX at baseline was not signiﬁcant differences between K/L
grades. Among the patients with K/L grade 1 to 3, the baseline ln-uCTX-
II levels in the patients with progression of K/L grade were signiﬁcantly
higher than the patients with no progression of K/L grade (p ¼ 0.002).
Conclusions: We demonstrated in the present study that the patients
who were progressed OA presented by K/L grade during 3 years had a
higher uCTX-II, cartilage degradation marker, levels than the others.
These ﬁndings suggest that we could predict OA progression at the ﬁrst
visit in the hospital be using biomarkers. In conclusion, uCTX-II could
predict OA progression.
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COLL2-1NO2: A BIOMARKER FOR EARLY KNEE OSTEOARTHRITIS?
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Purpose: To investigate the association between urinary degradation
biomarker Coll2-1NO2 (uColl2-1NO2) and incident knee OA after 2.5
years in middle-aged overweight women at high risk for knee OA.
Secondly, to assess association of uColl2-1NO2 with cartilage loss pro-
gression on magnetic resonance imaging (MRI).
Methods: Data were used from PROOF, a 2.5 years randomized con-
trolled trial evaluating the preventive effects of a diet and exercise
program and of oral glucosamine sulphate (double blind and placebo
controlled), on development of knee OA in women with body mass
index  27 kg/m2 and without knee OA at baseline. Baseline, 1 and 2.5
years uColl2-1NO2 levels were assessed with ELISA. Primary outcome
measure was incidence of knee OA in one or both knees, deﬁned as
incidence of either Kellgren & Lawrence grade  2, joint space nar-
rowing of  1.0 mm or clinical knee OA according to the combined
clinical and radiographic ACR-criteria. Secondary outcome measures
were the separate radiographic and clinical items and the MRI pro-
gression of cartilage loss in the patellofemoral and tibiofemoral joint,
using the MRI Osteoarthritis Knee Score (MOAKS). Association between
baseline, follow-up and change of uColl2-1NO2 with primary and sec-
ondary outcomes were assessed using binary logistic regression
analyses.
Results: 254 women were available for primary analysis, 234 women
for MRI analyses. After 2.5 years follow-up, knee OA developed in 72 of
254 women (28.3%) and progression of cartilage defects in 115 of 234
women (49.1%). An inversed association was found between baseline
uColl2-1NO2 and incident knee OA (OR 0.74, 95% CI 0.55 – 0.99) after 2.5
years follow-up. A trend of increasing uColl2-1NO2 during follow-up of
2.5 years was found in incident knee OA and in progression of cartilage
defects (OR 1.10, 95% CI 0.81 – 1.48 and OR 1.26, 95% CI 0.93 – 1.70respectively). This trend of increasing uColl2-1NO2 is also shown in the
ﬁgure.
Conclusion: In overweight middle-aged women, low baseline uColl2-
1NO2 levels were associated with an increased risk for incident knee
OA. We can propose different hypothesis to explain this ﬁnding: 1) an
anabolic compensatory mechanism active in early knee OA, 2) in con-
trast, a decrease of cartilage metabolism could precede cartilage deg-
radation; 3) cartilage volume is lower in people developing knee OA.
Overall, after lower baseline uColl2-1NO2, increasing uColl2-1NO:2
levels seem to dominate in further OA development. Although in early
knee OA changes in uColl2-1NO2 can be found, further exploring of the
biomarker ﬁeld seems necessary to better understand the onset of OA in
high risk patients.123
CORRELATION ANALYSIS OF INFLAMMATION BIOMARKERS WITH
CLINICAL SCORES OF TISSUEGENE-C (TG-C)
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Inc., Gwacheon-si, Republic of Korea
Purpose: Osteoarthritis (OA) is a degenerative joint disease caused by
unbalanced anabolism and catabolism of cartilage with a mild inﬂam-
matory response, but little is known about how the level of inﬂam-
mation is related to severity of OA symptom and tissue destruction. The
level of circulating acute phase protein, C-reactive protein (CRP) has
been widely used as a diagnostic marker in acute inﬂammatory dis-
eases. The matrix metalloproteinase-mediated C-reactive protein
(CRPM) is a hallmark of chronic tissue inﬂammation in the knee joint of
OA patients. TG-C is a cell mediated gene therapy product that contains
non-transduced (hChonJ) and transduced (hChonJb#7) human alloge-
neic chondrocytes. The hChonJb#7 cells were transduced with TGF-b1
gene-containing retroviral vector. The aim of this study was to evaluate
correlation between inﬂammatory biomarkers in OA patients and the
changes of clinical scores of IKDC and WOMAC to estimate the prog-
nostic feature for this TG-C therapy.
Methods: Data from clinical scores of IKDC, WOMAC, IKDC6-0(the
changed value of IKDC score evaluated 6months post treatment of TG-
C) and WOMAC6-0(the changed value of WOMAC score evaluated 6
months post treatment of TG-C) were collected from patients during
TG-C clinical trials, phase IIa (KS-TGC-01-2a) and phase IIb (KS-TGC-01-
2b). The patients enrolled in the clinical trials of TG-C included
advanced joint damage (K&L grade 3, ICRS grade IV in main cartilage
lesion) and various range of knee clinical scores (Table 1). The level of
serum high sensitive CRP (hsCRP) and CRPM were detected by enzyme
linked immunosorbent assay (ELISA). The values were compared
between studies and treatment groups within each study by a non-
